Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry

Wen Chan Hsu, Shun Pang Chang, Lie Chwen Lin, Chia Lin Li, Christopher D. Richardson, Chun Ching Lin, Liang Tzung Lin

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

A preventive vaccine against hepatitis C virus (HCV) infection remains unavailable and newly developed drugs against viral replication are complicated by potential drug-resistance and high cost. These issues justify the need to develop alternative antiviral agents and expand the scope of strategies for the treatment of hepatitis C, such as targeting viral entry. In this study, we explore the bioactivity of Limonium sinense (L. sinense) and its purified constituents against HCV life cycle using subgenomic replicon and infectious HCV culture systems. Data indicated that the water extract from the underground part of L. sinense (LS-UW) exhibited potent inhibitory activity against HCV at non-cytotoxic concentrations. LS-UW targeted early HCV infection without affecting viral replication, translation, and cell-to-cell transmission, and blocked viral attachment and post-attachment entry/fusion steps. Bioactivity analysis of major constituents from LS-UW through viral infectivity/entry assays revealed that gallic acid (GA) also inhibits HCV entry. Furthermore, both LS-UW and GA could suppress HCV infection of primary human hepatocytes. Due to their potency and ability to target HCV early viral entry, LS-UW and GA may be of value for further development as prospective antivirals against HCV.

Original languageEnglish
Pages (from-to)139-147
Number of pages9
JournalAntiviral Research
Volume118
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Plumbaginaceae
Gallic Acid
Virus Diseases
Hepacivirus
Antiviral Agents
Hepatovirus
Virus Internalization
Replicon
Groundwater
Hepatitis C
Life Cycle Stages
Drug Resistance
Hepatocytes
Vaccines

Keywords

  • Antivirals
  • Gallic acid
  • Hepatitis C virus
  • Limonium sinense
  • Natural products
  • Viral entry inhibition

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry. / Hsu, Wen Chan; Chang, Shun Pang; Lin, Lie Chwen; Li, Chia Lin; Richardson, Christopher D.; Lin, Chun Ching; Lin, Liang Tzung.

In: Antiviral Research, Vol. 118, 01.06.2015, p. 139-147.

Research output: Contribution to journalArticle

Hsu, Wen Chan ; Chang, Shun Pang ; Lin, Lie Chwen ; Li, Chia Lin ; Richardson, Christopher D. ; Lin, Chun Ching ; Lin, Liang Tzung. / Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry. In: Antiviral Research. 2015 ; Vol. 118. pp. 139-147.
@article{4bc654161cd14f3cbf555a81af3aa7c7,
title = "Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry",
abstract = "A preventive vaccine against hepatitis C virus (HCV) infection remains unavailable and newly developed drugs against viral replication are complicated by potential drug-resistance and high cost. These issues justify the need to develop alternative antiviral agents and expand the scope of strategies for the treatment of hepatitis C, such as targeting viral entry. In this study, we explore the bioactivity of Limonium sinense (L. sinense) and its purified constituents against HCV life cycle using subgenomic replicon and infectious HCV culture systems. Data indicated that the water extract from the underground part of L. sinense (LS-UW) exhibited potent inhibitory activity against HCV at non-cytotoxic concentrations. LS-UW targeted early HCV infection without affecting viral replication, translation, and cell-to-cell transmission, and blocked viral attachment and post-attachment entry/fusion steps. Bioactivity analysis of major constituents from LS-UW through viral infectivity/entry assays revealed that gallic acid (GA) also inhibits HCV entry. Furthermore, both LS-UW and GA could suppress HCV infection of primary human hepatocytes. Due to their potency and ability to target HCV early viral entry, LS-UW and GA may be of value for further development as prospective antivirals against HCV.",
keywords = "Antivirals, Gallic acid, Hepatitis C virus, Limonium sinense, Natural products, Viral entry inhibition",
author = "Hsu, {Wen Chan} and Chang, {Shun Pang} and Lin, {Lie Chwen} and Li, {Chia Lin} and Richardson, {Christopher D.} and Lin, {Chun Ching} and Lin, {Liang Tzung}",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.antiviral.2015.04.003",
language = "English",
volume = "118",
pages = "139--147",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",

}

TY - JOUR

T1 - Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry

AU - Hsu, Wen Chan

AU - Chang, Shun Pang

AU - Lin, Lie Chwen

AU - Li, Chia Lin

AU - Richardson, Christopher D.

AU - Lin, Chun Ching

AU - Lin, Liang Tzung

PY - 2015/6/1

Y1 - 2015/6/1

N2 - A preventive vaccine against hepatitis C virus (HCV) infection remains unavailable and newly developed drugs against viral replication are complicated by potential drug-resistance and high cost. These issues justify the need to develop alternative antiviral agents and expand the scope of strategies for the treatment of hepatitis C, such as targeting viral entry. In this study, we explore the bioactivity of Limonium sinense (L. sinense) and its purified constituents against HCV life cycle using subgenomic replicon and infectious HCV culture systems. Data indicated that the water extract from the underground part of L. sinense (LS-UW) exhibited potent inhibitory activity against HCV at non-cytotoxic concentrations. LS-UW targeted early HCV infection without affecting viral replication, translation, and cell-to-cell transmission, and blocked viral attachment and post-attachment entry/fusion steps. Bioactivity analysis of major constituents from LS-UW through viral infectivity/entry assays revealed that gallic acid (GA) also inhibits HCV entry. Furthermore, both LS-UW and GA could suppress HCV infection of primary human hepatocytes. Due to their potency and ability to target HCV early viral entry, LS-UW and GA may be of value for further development as prospective antivirals against HCV.

AB - A preventive vaccine against hepatitis C virus (HCV) infection remains unavailable and newly developed drugs against viral replication are complicated by potential drug-resistance and high cost. These issues justify the need to develop alternative antiviral agents and expand the scope of strategies for the treatment of hepatitis C, such as targeting viral entry. In this study, we explore the bioactivity of Limonium sinense (L. sinense) and its purified constituents against HCV life cycle using subgenomic replicon and infectious HCV culture systems. Data indicated that the water extract from the underground part of L. sinense (LS-UW) exhibited potent inhibitory activity against HCV at non-cytotoxic concentrations. LS-UW targeted early HCV infection without affecting viral replication, translation, and cell-to-cell transmission, and blocked viral attachment and post-attachment entry/fusion steps. Bioactivity analysis of major constituents from LS-UW through viral infectivity/entry assays revealed that gallic acid (GA) also inhibits HCV entry. Furthermore, both LS-UW and GA could suppress HCV infection of primary human hepatocytes. Due to their potency and ability to target HCV early viral entry, LS-UW and GA may be of value for further development as prospective antivirals against HCV.

KW - Antivirals

KW - Gallic acid

KW - Hepatitis C virus

KW - Limonium sinense

KW - Natural products

KW - Viral entry inhibition

UR - http://www.scopus.com/inward/record.url?scp=84927929074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927929074&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2015.04.003

DO - 10.1016/j.antiviral.2015.04.003

M3 - Article

VL - 118

SP - 139

EP - 147

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

ER -